Teva Pharma Q3 Beats Market, Lifts FY24 Outlook
Teva Pharma Q3 Beats Market, Lifts FY24 Outlook; Stock Up
In pre-market activity on the NYSE, TEVA shares were gaining around 3.1 percent to trade at $19.35. In the third quarter, net loss attributable to Teva was $437 million or $0.39 per share, compared to prior year's net income of $69 million or $0.
Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) – Investment analysts at Zacks Research lifted their ...
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today ...
JERUSALEM (Reuters) - Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in ...
UBS walked away from meetings with Teva (TEVA) management confident that the firm’s bullish thesis with a Street-high price target of $26 ...
Teva Pharmaceutical Industries Ltd (TEVA) reports a 15% revenue increase and raises 2024 guidance, despite facing legal and ...
In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) will be announcing its earnings results before the market opens ...
Teva Pharmaceutical Industries Limited ( (TEVA) ) has released its Q3 earnings. Here is a breakdown of the information Teva Pharmaceutical ...
Teva Pharmaceutical Industries Ltd. has been fined nearly €463 million ($503 million) by the European Union’s antitrust ...
EPS, expectations were $0.66. Operator: Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited Earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback